Department of Surgery, St Thomas' Hospital, London, United Kingdom; Department of Surgery, Royal Marsden Hospital, London, United Kingdom; Unit of Upper Gastrointestinal Research, Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden; Division of Cancer Studies, King's College London, London, United Kingdom.
J Surg Oncol. 2014 Apr;109(5):459-64. doi: 10.1002/jso.23511. Epub 2013 Dec 2.
Accurate selection of patients for radical treatment of esophageal cancer is essential to avoid early recurrence and death (ERD) after surgery. We sought to evaluate a large series of consecutive resections to assess factors that may be associated with this poor outcome.
This was a cohort study including 680 patients operated for esophageal cancer between 2000 and 2010. The poor outcome group comprised 100 patients with tumor recurrence and death within 1 year of surgery. The comparison group comprised 267 long-term survivors, defined as those surviving more than 3 years from surgery. Pathological characteristics associated with poor outcome were analyzed using logistic regression to determine odds ratios (OR) and 95% confidence intervals (CI).
On the adjusted model T stage and N stage predicted poor survival, with the greatest risk being patients with locally advanced tumors and three or more involved lymph nodes (OR 10.6, 95% CI 2.8-40.0). Poor differentiation (OR 2.8, 95% CI 1.4-5.5), chemotherapy response (OR 3.6, 95% CI 1.2-10.6), and involved resection margins (OR 2.7, 95% CI 1.2-6.0) were all significant independent prognostic markers in the multivariable model. There was a trend toward worse survival with lymphovascular invasion (OR 2.0, 95% CI 0.9-4.2) and low albumin (OR 1.9, 95% CI 0.8-4.4) but not of statistical significance in the adjusted model.
Esophageal cancer patients with poorly differentiated tumors and three or more involved lymph nodes have a particularly high risk of ERD after surgery. Accurate risk stratification of patients may identify a group who would be better served by alternative oncological treatment strategies.
准确选择接受根治性治疗的食管癌患者对于避免手术后早期复发和死亡(ERD)至关重要。我们旨在评估一系列连续切除术,以评估可能与这种不良结局相关的因素。
这是一项队列研究,纳入了 2000 年至 2010 年间接受食管癌手术的 680 例患者。不良结局组包括 100 例术后 1 年内肿瘤复发和死亡的患者。对照组包括 267 例长期幸存者,定义为术后 3 年以上存活的患者。使用逻辑回归分析来分析与不良结局相关的病理特征,以确定比值比(OR)和 95%置信区间(CI)。
在调整后的模型中,T 分期和 N 分期预测生存不良,风险最大的是局部进展期肿瘤和 3 个或更多受累淋巴结的患者(OR 10.6,95%CI 2.8-40.0)。低分化(OR 2.8,95%CI 1.4-5.5)、化疗反应(OR 3.6,95%CI 1.2-10.6)和受累切缘(OR 2.7,95%CI 1.2-6.0)在多变量模型中均为显著独立预后标志物。淋巴血管侵犯(OR 2.0,95%CI 0.9-4.2)和低白蛋白血症(OR 1.9,95%CI 0.8-4.4)的生存趋势较差,但在调整后的模型中无统计学意义。
低分化肿瘤和 3 个或更多受累淋巴结的食管癌患者手术后 ERD 的风险特别高。对患者进行准确的风险分层可能会发现一组患者可能受益于替代肿瘤治疗策略。